Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Transport of Plasma Samples to Bioanalytical Lab – V 2.0

Posted on By

BA-BE Studies: SOP for Transport of Plasma Samples to Bioanalytical Lab – V 2.0

Standard Operating Procedure for Transport of Plasma Samples to Bioanalytical Lab

Department BA-BE Studies
SOP No. SOP/BA-BE/094/2025
Supersedes SOP/BA-BE/094/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized and compliant procedure for the transport of plasma samples collected during BA/BE studies from the clinical site to the designated bioanalytical laboratory, maintaining sample integrity, cold chain, and traceability throughout the process.

2. Scope

This SOP applies to all personnel involved in the packaging, labeling, documentation, and physical transport of plasma samples during

BA/BE clinical studies conducted at the research facility.

3. Responsibilities

  • Clinical Research Coordinator (CRC): Coordinates labeling and documentation of samples for dispatch.
  • Sample Handler/Technician: Ensures proper packaging, temperature monitoring, and handover to courier or internal transport team.
  • Quality Assurance (QA): Reviews sample transport logs and ensures adherence to SOP.
  • Transport Personnel: Ensures safe delivery and documentation of receipt at the bioanalytical lab.
See also  BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period - V 2.0

4. Accountability

The Principal Investigator (PI) is accountable for ensuring that plasma samples are transported under validated conditions without compromising quality or traceability.

5. Procedure

5.1 Sample Preparation and Packaging

  1. Ensure all plasma samples are properly aliquoted, labeled with:
    • Study ID
    • Subject ID
    • Timepoint
    • Visit date
  2. Place labeled samples in cryoboxes and wrap with absorbent material.
  3. Insert cryoboxes into validated cold chain transport containers pre-chilled to -20°C or as per protocol.
  4. Include a temperature monitoring device (e.g., data logger or freeze tag).

5.2 Documentation

  1. Prepare Annexure-1: Plasma Sample Dispatch Form containing:
    • Study code, sample IDs, timepoints, and box details
    • Transporter’s name and signature
  2. Place a copy inside the transport container and retain one copy at site.
See also  BA-BE Studies: SOP for Third-Party Vendor Qualification (Labs, Courier) - V 2.0

5.3 Transport Conditions

  1. Ensure containers are validated for maintaining required temperature for the expected transport duration.
  2. Mark the box with:
    • “Human Biological Samples – Handle with Care”
    • “Maintain Cold Chain”
  3. Ensure transit time is minimized and direct delivery is preferred.

5.4 Receipt and Handover at Bioanalytical Lab

  1. Upon arrival, the receiving lab staff verifies:
    • Seals and label integrity
    • Sample condition and quantity
    • Temperature log compliance
  2. Receiving person signs Annexure-2: Sample Receipt Acknowledgment Form.

5.5 Deviations and Excursions

  1. If temperature excursion or sample damage is observed:
    • Document incident in Annexure-3: Sample Transport Deviation Log
    • Inform QA and PI immediately

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • PI: Principal Investigator

7. Documents

  1. Plasma Sample Dispatch Form – Annexure-1
  2. Sample Receipt Acknowledgment Form – Annexure-2
  3. Sample Transport Deviation Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • WHO Guidance on Transport of Infectious Substances
  • Study Protocol and Bioanalytical SOPs
See also  BA-BE Studies: SOP for Clinical Site Monitoring Visits - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Plasma Sample Dispatch Form

Study Code Box ID Sample IDs Date Sent By Signature
BE/2025/094 BOX-01 VOL-101 to VOL-110 17/04/2025 Sunita Reddy Signed

Annexure-2: Sample Receipt Acknowledgment Form

Date Received Received By Sample Condition Seal Intact Remarks
17/04/2025 Ajay Verma Acceptable Yes Transport validated

Annexure-3: Sample Transport Deviation Log

Date Box ID Deviation Action Taken Notified To
17/04/2025 BOX-02 Temperature > -15°C Samples quarantined QA & PI

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial Release Study Start QA Head
17/04/2025 2.0 Added deviation log and updated documentation forms Audit Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Temperature Mapping in Drying Chambers – V 2.0
Next Post: Creams: SOP for Conducting Rheological Analysis of Creams – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version